New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:32 EDTXOMAXOMA downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse downgraded XOMA following the Phase II trial failure of gevokizumab in Erosive Osteoarthritis of the Hand.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
11:06 EDTXOMAXOMA price target raised to $1.50 from $1 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for XOMA (XOMA) to $1.50 after the company partnered a preclinical TGF-beta antibody with Novartis (NVS) for $37M upfront and up to $480M in milestones. The payment brings XOMA's pro forma cash to $88M, enabling the company to advance its endocrine antibody pipeline, including lead candidate XOMA 358 for hyperinsulinism disorders, Tenthoff tells investors in a research note. The analyst keeps a Neutral rating on the name. The stock is up 20c to 95c in early trading.
09:20 EDTXOMAOn The Fly: Pre-market Movers
HIGHER: XOMA (XOMA), up 55.7% after announcing an agreement for anti-TGFb program with Novartis (NVS)... Sarepta Therapeutics (SRPT), up 10.6% after announcing additional clinical efficacy and safety data from the company's Phase IIb program of eteplirsen... Huntsman (HUN), up 3.8% after announcing a $150M share repurchase program... Mellanox (MLNX), up 3.2% after raising third quarter revenue guidance. DOWN AFTER EARNINGS: McCormick (MKC), down 3.4%. ALSO LOWER: Capstone Turbine (CPST), down 26.5% after announcing that its preliminary second quarter earnings were notably below management's expectations and analysts' consensus estimates... Concho Resources (CXO), down 3.9% after 7.7M share Spot Secondary priced at $92.50... AGCO (AGCO), down 3.5% after being downgraded to Sell from Neutral at UBS.
07:37 EDTXOMAXOMA announces agreement for anti-TGFb program with Novartis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use